UNLABELLED: We developed a radioligand, 3-fluoro-5-(2-(2-(18)F-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile ((18)F-SP203), for metabotropic glutamate subtype 5 (mGluR5) receptors that showed both promising (high specific binding) and problematic (defluorination) imaging characteristics in animals. The purposes of this initial evaluation in human subjects were to determine whether (18)F-SP203 is defluorinated in vivo (as measured by uptake of radioactivity in the skull) and to determine whether the uptake in the brain can be quantified as distribution volume relative to concentrations of (18)F-SP203 in plasma. METHODS: Seven healthy subjects were injected with (18)F-SP203 (323 +/- 87 MBq) and scanned over 5 h, with rest periods outside the camera. The concentrations of (18)F-SP203, separated from radiometabolites, were measured in arterial plasma. RESULTS: The skull was difficult to visualize on PET images in the initial 2 h, because of high radioactivity in the brain. Although radioactivity in the skull and adjacent cortex showed some cross-contamination, the concentration of radioactivity in the skull was less than half of that in the adjacent cortex during the initial 2 h. Modeling of regional brain and plasma data showed that a 2-tissue-compartment model was superior to a 1-tissue-compartment model, consistent with measurable amounts of both receptor-specific and nonspecific binding. The concentrations of activity in the brain measured with PET were consistently greater than the modeled values at late but not early time points and may well have been caused by the slow accumulation of radiometabolites in the brain. To determine an adequate time for more accurate measurement of distribution volume, we selected a scan duration (i.e., 2 h) associated with maximal or near-maximal identifiability. Distribution volume was well identified ( approximately 2%) by only 2 h (and even just 1) of image acquisition. CONCLUSION: This initial evaluation of (18)F-SP203 in healthy human subjects showed that defluorination is relatively small and that brain uptake can be robustly calculated as distribution volume. The values of distribution volume were well identified and had relatively small variation in this group of 7 subjects. These results suggest that (18)F-SP203 will have good sensitivity to measure mGluR5 receptors for both within-subject studies (e.g., receptor occupancy) and between-subject studies (e.g., patients vs. healthy subjects).
UNLABELLED: We developed a radioligand, 3-fluoro-5-(2-(2-(18)F-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile ((18)F-SP203), for metabotropic glutamate subtype 5 (mGluR5) receptors that showed both promising (high specific binding) and problematic (defluorination) imaging characteristics in animals. The purposes of this initial evaluation in human subjects were to determine whether (18)F-SP203 is defluorinated in vivo (as measured by uptake of radioactivity in the skull) and to determine whether the uptake in the brain can be quantified as distribution volume relative to concentrations of (18)F-SP203 in plasma. METHODS: Seven healthy subjects were injected with (18)F-SP203 (323 +/- 87 MBq) and scanned over 5 h, with rest periods outside the camera. The concentrations of (18)F-SP203, separated from radiometabolites, were measured in arterial plasma. RESULTS: The skull was difficult to visualize on PET images in the initial 2 h, because of high radioactivity in the brain. Although radioactivity in the skull and adjacent cortex showed some cross-contamination, the concentration of radioactivity in the skull was less than half of that in the adjacent cortex during the initial 2 h. Modeling of regional brain and plasma data showed that a 2-tissue-compartment model was superior to a 1-tissue-compartment model, consistent with measurable amounts of both receptor-specific and nonspecific binding. The concentrations of activity in the brain measured with PET were consistently greater than the modeled values at late but not early time points and may well have been caused by the slow accumulation of radiometabolites in the brain. To determine an adequate time for more accurate measurement of distribution volume, we selected a scan duration (i.e., 2 h) associated with maximal or near-maximal identifiability. Distribution volume was well identified ( approximately 2%) by only 2 h (and even just 1) of image acquisition. CONCLUSION: This initial evaluation of (18)F-SP203 in healthy human subjects showed that defluorination is relatively small and that brain uptake can be robustly calculated as distribution volume. The values of distribution volume were well identified and had relatively small variation in this group of 7 subjects. These results suggest that (18)F-SP203 will have good sensitivity to measure mGluR5 receptors for both within-subject studies (e.g., receptor occupancy) and between-subject studies (e.g., patients vs. healthy subjects).
Authors: N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot Journal: Neuroimage Date: 2002-01 Impact factor: 6.556
Authors: Abdelmalik Slassi; Methvin Isaac; Louise Edwards; Alexander Minidis; David Wensbo; Jan Mattsson; Karolina Nilsson; Patrick Raboisson; Donald McLeod; Thomas M Stormann; Lance G Hammerland; Edwin Johnson Journal: Curr Top Med Chem Date: 2005 Impact factor: 3.295
Authors: Simon M Ametamey; Lea J Kessler; Michael Honer; Matthias T Wyss; Alfred Buck; Samuel Hintermann; Yves P Auberson; Fabrizio Gasparini; Pius A Schubiger Journal: J Nucl Med Date: 2006-04 Impact factor: 10.057
Authors: Simon M Ametamey; Valerie Treyer; Johannes Streffer; Matthias T Wyss; Mark Schmidt; Milen Blagoev; Samuel Hintermann; Yves Auberson; Fabrizio Gasparini; Uta C Fischer; Alfred Buck Journal: J Nucl Med Date: 2007-02 Impact factor: 10.057
Authors: Valerie Treyer; Johannes Streffer; Simon M Ametamey; Andrea Bettio; Peter Bläuenstein; Mark Schmidt; Fabrizio Gasparini; Uta Fischer; Christoph Hock; Alfred Buck Journal: Eur J Nucl Med Mol Imaging Date: 2007-12-11 Impact factor: 9.236
Authors: H Umesha Shetty; Sami S Zoghbi; Fabrice G Siméon; Jeih-San Liow; Amira K Brown; Pavitra Kannan; Robert B Innis; Victor W Pike Journal: J Pharmacol Exp Ther Date: 2008-09-19 Impact factor: 4.030
Authors: Kristina Herfert; Julia G Mannheim; Laura Kuebler; Sabina Marciano; Mario Amend; Christoph Parl; Hanna Napieczynska; Florian M Maier; Salvador Castaneda Vega; Bernd J Pichler Journal: Mol Imaging Biol Date: 2020-04 Impact factor: 3.488
Authors: Jinsoo Hong; Shuiyu Lu; Rong Xu; Jeih-San Liow; Alicia E Woock; Kimberly J Jenko; Robert L Gladding; Sami S Zoghbi; Robert B Innis; Victor W Pike Journal: Nucl Med Biol Date: 2015-07-23 Impact factor: 2.408
Authors: Fabrice G Siméon; Jeih-San Liow; Yi Zhang; Jinsoo Hong; Robert L Gladding; Sami S Zoghbi; Robert B Innis; Victor W Pike Journal: Eur J Nucl Med Mol Imaging Date: 2012-08-11 Impact factor: 9.236